Skip to main content

Table 1 Demographics of the total patient cohort, and in renal allograft recipients without and with herpes virus or polyoma virus viremia

From: Transplant centers’ prophylaxis and monitoring strategies: a key determinant of current herpes and polyomavirus incidences – results from the DZIF kidney transplant cohort

 

Total cohort

No viremia

CMV

viremia

Other herpes viruses

BKV

viremia

CMV/

BKV co-viremia

Total number of patients

1035

767

144

31

132

23

Demographics

      

Age at tx

(Mean ± SD, range)

51 ± 14 18–79

51 ± 14 18–78

50 ± 13

19–78

53 ± 12

20–79

52 ± 13

22–79

49 ± 13

25–76

< 50 years

413 (40.0)

309 (40.4)

59 (41.0)

8 (25.8)

49 (37.1)

10 (43.5)

50–65 years

448 (43.4)

318 (41.6)

70 (48.6)

19 (61.3)

66 (50.0)

12 (52.2)

> 65 years

170 (16.5)

138 (18.0)

15 (10.4)

4 (12.9)

17 (12.9)

1 (4.3)

Male gender

654 (64.6)

473 (63.6)

94 (65.2)

23 (74.2)

97 (73.5)

19 (82.6)

Clinical data

      

Cause of ESRD

      

Glomerulonephritis

321 (31.5)

224 (29.6)

55 (38.5)

13 (43.3)

43 (33.1)

8 (34.8)

APKD

147 (14.4)

113 (14.9)

16 (11.2)

6 (20.0)

21 (16.2)

5 (21.7)

Diabetes mellitus

105 (10.3)

82 (10.8)

16 (11.2)

3 (15.0)

7 (5.4)

1 (4.3)

Nephrosclerosis

54 (5.3)

46 (6.1)

4 (2.8)

1 (3.3)

3 (2.3)

0 (0.0)

Interstinal Nephritis

32 (3.1)

23 (3.0)

3 (2.1)

0 (0.0)

8 (6.2)

2 (8.7)

Vasculitis and Collagenoses

29 (2.8)

20 (2.6)

4 (2.8)

0 (0.0)

5 (3.8)

0 (0.0)

Urological diseases

22 (2.2)

19 (2.5)

1 (0.7)

1 (3.3)

2 (1.5)

0 (0.0)

Other hereditary diseases

59 (5.8)

41 (5.4)

9 (6.3)

1 (3.3)

12 (9.2)

4 (17.4)

Other

251 (24.6)

190 (25.1)

32 (22.4)

5 (16.7)

29 (22.3)

3 (13.0)

Body mass index (mean ± SD) in kg/m2

25 ± 4

26 ± 5

25 ± 4

25 ± 4

25 ± 4

25 ± 4

Donor characteristics

      

Age group

      

< 35

107 (11.0)

86 (12.0)

10 (7.1)

1 (3.3)

11 (8.5)

0 (0.0)

≥ 35 to < 60

459 (47.0)

337 (47.2)

66 (47.1)

19 (63.3)

56 (43.1)

10 (45.5)

≥ 60

411 (42.1)

291 (40.8)

64 (45.7)

10 (61.3)

63 (48.5)

12 (54.5)

Male sex

381 (43.0)

290 (44.3)

46 (37.7)

14 (33.3)

45 (38.8)

7 (36.8)

CMV serologies

      

D+/ R-

204 (20.9)

126 (17.5)

57 (41.6)

0 (0.0)

33 (25.4)

12 (54.5)

D+/ R+

349 (35.7)

266 (37.0)

46 (33.6)

6 (20.0)

40 (30.8)

6 (27.3)

D-/ R+

201 (20.6)

151 (21.0)

30 (21.9)

7 (23.3)

21 (16.2)

3 (13.6)

D-/ R-

225 (23.0)

176 (24.5)

4 (2.9)

17 (56.7)

36 (27.7)

1 (4.5)

Type of transplantation

      

Living donation

341 (33.1)

267 (34.9)

30 (21.0)

11 (35.5)

41 (31.3)

3 (13.6)

Pancreas-kidney

56 (5.4)

40 (5.2)

12 (8.3)

1 (3.2)

4 (3.0)

1 (4.3)

AB0-Incompatibility

57 (5.9)

45 (6.4)

6 (4.3)

1 (3.2)

6 (4.6)

1 (4.3)

Previous transplantation

168 (16.2)

122 (15.9)

23 (16.0)

6 (19.6)

24 (18.2)

5 (21.7)

Immunized transplantation

81 (8.3)

49 (6.9)

47 (33.8)

12 (40.0)

13 (10.0)

2 (9.1)

ESP

130 (12.6)

108 (14.0)

11 (7.6)

3 (9.7)

11 (8.3)

0 (0.0)

Immunosuppression

      

Induction therapy

      

Basiliximab

863 (83.4)

654 (84.7)

110 (78.6)

24 (77.4)

107 (81.1)

17 (73.9)

Thymoglobuline

172 (16.6)

117 (15.3)

34 (23.6)

7 (22.6)

25 (18.9)

6 (26.1)

Plasmapheresis

141 (13.6)

95 (12.4)

29 (20.1)

3 (9.7)

22 (16.7)

6 (26.1)

Conditioning treatment†

285 (28.9)

200 (27.9)

55 (38.5)

13 (41.9)

41 (31.3)

9 (39.1)

Maintenance therapy at discharge

      

Tacrolimus + MPA/MMF + Steroids

674 (79.1)

472 (77.9)

109 (82.6)

21 (70.0)

102 (86.4)

17 (89.5)

Ciclosporine A + MPA/MMF + Steroids

175 (20.5)

133 (21.9)

23 (17.4)

9 (30.0)

16 (13.6)

2 (10.5)

Tacrolimus + Azathioprine + Steroids

2 (0.2)

2 (0.3)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Antimicrobial Prophylaxis

      

CMV-prophylaxis

772

(75.9)

493

(75.6)

126

(89.4)

12

(40.0)

89

(78.1)

17

(85.0)

Postoperative variables

      

In-patient stay, (Md, IQR)

17, 12–24

17, 12–24

19, 14–26

17, 14–28

16, 13–22

18, 14–25

Delayed graft function‡

195 (19.1)

138 (18.3)

32 (22.2)

7 (22.6)

21 (16.0)

1 (4.3)

  1. Data presented as numbers (%) unless otherwise indicated. Missing values were excluded.
  2. Other herpes viruses included HSV-1 (n = 15), HSV-2 (n = 6), VZV (n = 9), EBV (n = 5), HHV-6 (n = 1).
  3. Abbreviations: tx = transplantation, ESRD = end-stage renal disease, APKD = autosomal polycystic kidney disease, CMV = Cytomegalovirus, BKV = BK-virus, HSV = Herpes simplex virus, VZV = Varicella zoster virus, EBV = Epstein-Barr-virus, HHV-6 = Human Herpesvirus 6, R+/-=recipient positive/negative, D+/-=donor positive/negative, ESP = Eurotransplant Senior Program, MPA = Mycophenolic acid, MMF = Mycophenolate mofetil; C0 = trough level, CsA = Ciclosporin A, Tac = tacrolimus, SD = standard deviation, Md = median, IQR = interquartile range. Plasmapheresis, Thymoglobuline Rituximab etc. before transplantation
  4. ‡Need for hemodialysis within the first 7 days post-transplantation
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us